小分子靶向抗肿瘤药评价的整体考虑

Overall consideration in the evaluation of small molecular targeted anti-tumor drugs

近年来,靶向治疗成为抗肿瘤治疗领域的研发热点。与传统细胞毒类药物作用机制相比,靶向药物更具特异性,通过对细胞信号转导通道的特异性靶点发挥作用,阻滞肿瘤细胞的生长,对正常细胞的作用相对较小,因此,毒性作用较传统细胞毒类药物相对较轻。针对急剧增长的小分子靶向药物研发和申报现状,本文就我中心对此类问题的认识和整体考虑进行阐述。

In recent years, targeted therapy in the field of anti-tumor therapy becomes a hot topic. Com- pared with the mechanisms of conventional cytotoxic drugs, targeted drugs are more specific, which can block the growth of tumor cells and affect the normal cells less, so the toxicity of the targeted drugs is less than that of the conventional cytotoxic drugs. Against a sharp increase of application and research in small molecular targeted drugs, we will talk about our understanding for this problem and the overall consideration in this paper.